Essential thrombocytosis diagnostic criteria: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
==Diagnostic criteria== | ==Diagnostic criteria== | ||
*Diagnosis requires meeting all the following four criteria as proposed by WHO in their revised WHO criteria for essential thrombocythemia<ref name="pmidhttp://dx.doi.org/10.1182/blood-2007-04-083501">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1182/blood-2007-04-083501 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> : | *Diagnosis requires meeting all the following four criteria as proposed by [[WHO]] in their revised WHO criteria for essential thrombocythemia<ref name="pmidhttp://dx.doi.org/10.1182/blood-2007-04-083501">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1182/blood-2007-04-083501 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> : | ||
**1. Sustained platelet count 450 10^9/L* | **1. Sustained platelet count 450 10^9/L* | ||
**2. Bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes; no significant increase | **2. [[Bone marrow]] biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes; no significant increase or left-shift of neutrophil granulopoiesis or [[erythropoiesis]] | ||
**3. Not meeting WHO criteria for PV,† PMF,‡ CML,§ MDS,¶ or other myeloid neoplasm | **3. Not meeting WHO criteria for [[PV]],† [[PMF]],‡ [[CML]],§ [[MDS]],¶ or other myeloid neoplasm | ||
**4. Demonstration of | **4. Demonstration of [[JAK2]]617VF or other clonal marker, or in the absence of a clonal marker, no evidence for reactive thrombocytosis | ||
<sub>*During the work-up period. | <sub>*During the work-up period. | ||
†Requires the failure of iron replacement therapy to increase hemoglobin level to the PV range in the presence of decreased serum ferritin. Exclusion of PV is based on hemoglobin and hematocrit levels, and red cell mass measurement is not required. | †Requires the failure of iron replacement therapy to increase hemoglobin level to the PV range in the presence of decreased serum [[ferritin]]. Exclusion of PV is based on hemoglobin and hematocrit levels, and red cell mass measurement is not required. | ||
‡Requires the absence of relevant reticulin fibrosis, collagen fibrosis, peripheral blood leukoerythroblastosis, or markedly hypercellular marrow for age accompanied by megakaryocyte morphology that is typical for PMF small to large with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous or irregularly folded nuclei and dense clustering. § Requires the absence of BCR-ABL. | ‡Requires the absence of relevant [[reticulin]] fibrosis, [[collagen]] fibrosis, peripheral blood [[leukoerythroblastosis]], or markedly hypercellular marrow for age accompanied by megakaryocyte morphology that is typical for PMF small to large with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous or irregularly folded nuclei and dense clustering. § Requires the absence of [[BCR-ABL]]. | ||
¶Requires absence of dyserythropoiesis and dysgranulopoiesis. Causes of reactive thrombocytosis include iron deficiency, splenectomy, surgery, infection, inflammation, connective tissue disease, metastatic cancer, and lymphoproliferative disorders. However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of ET if the first three criteria are met.<sub> | ¶Requires absence of [[dyserythropoiesis]] and dysgranulopoiesis. Causes of reactive thrombocytosis include iron deficiency, [[splenectomy]], surgery, infection, inflammation, connective tissue disease, metastatic cancer, and [[lymphoproliferative]] disorders. However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of ET if the first three criteria are met.<sub> | ||
==References== | ==References== | ||
Revision as of 16:03, 6 November 2015
|
Essential thrombocytosis Microchapters |
|
Differentiating Essential thrombocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Essential thrombocytosis diagnostic criteria On the Web |
|
American Roentgen Ray Society Images of Essential thrombocytosis diagnostic criteria |
|
Risk calculators and risk factors for Essential thrombocytosis diagnostic criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]
Overview
Diagnostic criteria
- Diagnosis requires meeting all the following four criteria as proposed by WHO in their revised WHO criteria for essential thrombocythemia[1] :
- 1. Sustained platelet count 450 10^9/L*
- 2. Bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes; no significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis
- 3. Not meeting WHO criteria for PV,† PMF,‡ CML,§ MDS,¶ or other myeloid neoplasm
- 4. Demonstration of JAK2617VF or other clonal marker, or in the absence of a clonal marker, no evidence for reactive thrombocytosis
*During the work-up period. †Requires the failure of iron replacement therapy to increase hemoglobin level to the PV range in the presence of decreased serum ferritin. Exclusion of PV is based on hemoglobin and hematocrit levels, and red cell mass measurement is not required. ‡Requires the absence of relevant reticulin fibrosis, collagen fibrosis, peripheral blood leukoerythroblastosis, or markedly hypercellular marrow for age accompanied by megakaryocyte morphology that is typical for PMF small to large with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous or irregularly folded nuclei and dense clustering. § Requires the absence of BCR-ABL. ¶Requires absence of dyserythropoiesis and dysgranulopoiesis. Causes of reactive thrombocytosis include iron deficiency, splenectomy, surgery, infection, inflammation, connective tissue disease, metastatic cancer, and lymphoproliferative disorders. However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of ET if the first three criteria are met.
References
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1182/blood-2007-04-083501 Check
|pmid=value (help).